Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.

@article{Lavaud2018AnticancerAA,
  title={Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-na{\"i}ve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.},
  author={Pernelle Lavaud and Gw{\'e}naelle Gravis and St{\'e}phanie Foulon and Florence Joly and Stephane Oudard and Frank Priou and Igor Latorzeff and Lo{\"i}c Mourey and Michel Souli{\'e} and R{\'e}my Delva and Ivan Krakowski and Brigitte Laguerre and Christine Th{\'e}odore and Jean Marc Ferrero and Philippe Beuzeboc and Muriel Habibian and Fr{\'e}d{\'e}ric Rolland and Gael Deplanque and Damien Pouessel and Sylvie Zanetta and Jean François Berdah and J{\'e}r{\^o}me Dauba and Marjorie Baciuchka and Christian Platini and Claude Linassier and Nicole Tubiana-Mathieu and Jean Pascal Machiels and Claude El Kouri and Alain Mure Ravaud and Etienne Suc and Jean Christophe Eymard and Ali Hasbini and Guilhem Bousquet and St{\'e}phane Culine and Jean-Marie Boher and Gabrielle Tergemina-Clain and Cl{\'e}mence Legoupil and Karim S Fizazi},
  journal={European urology},
  year={2018},
  volume={73 5},
  pages={696-703}
}
BACKGROUND Androgen deprivation therapy (ADT) plus docetaxel is the standard of care in fit men with metastatic castration-naive prostate cancer (mCNPC) following results from GETUG-AFU 15, CHAARTED, and STAMPEDE. No data are available on the efficacy of treatments used for metastatic castration-resistant prostate cancer (mCRPC) in men treated upfront with ADT plus docetaxel for mCNPC. OBJECTIVE To investigate the efficacy and tolerance of subsequent treatments in patients treated upfront… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 52 times over the past 90 days. VIEW TWEETS